NCT01441479

Brief Summary

The purpose of this study is to demonstrate the ability of the Strep A Fluorescent Immunoassay Analyzer to accurately detect a throat swab specimen for the presence or absence of Strep A when compared to culture.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,282

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2011

Geographic Reach
1 country

7 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2011

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

September 23, 2011

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 27, 2011

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2012

Completed
Last Updated

February 7, 2013

Status Verified

December 1, 2012

Enrollment Period

1.5 years

First QC Date

September 23, 2011

Last Update Submit

February 5, 2013

Conditions

Outcome Measures

Primary Outcomes (1)

  • Streptococcus Group B identification

    The purpose of this study was to identify via immunofluorescence technology, Group A Streptococcus, which was successfully done.

    Immediate

Interventions

Eligibility Criteria

Age3 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Subjects must be greater than 3 years of age and exhibiting symptoms characteristic of pharyngitis, possibly Group A Streptococcus.

You may qualify if:

  • Male and female subjects three (3) years of age or older
  • Must currently be exhibiting one or more of the following symptoms characteristic of pharyngitis
  • Extreme sore throat
  • Redness of the posterior pharyngeal wall
  • Difficulty Swallowing
  • Fever, \>38.7C (100F) at presentation or within past 24 hours
  • Pharyngeal exudate
  • Tender cervical lymphadenopathy
  • Absence of cough or other upper respiratory symptoms

You may not qualify if:

  • Subjects currently under treatment with antibiotics are not to be included in this study.
  • At clinical sites requiring informed consent, unable to understand and consent to participation; for minors this includes parent or legal guardian.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (7)

Best Medical Group

Phoenix, Arizona, 85042, United States

Location

La Costa Pediatrics

Carlsbad, California, 92009, United States

Location

La Jolla Pediatrics

San Diego, California, 92121, United States

Location

Teena Hughes

Tampa, Florida, 33613, United States

Location

FastER Urgent Care

Morris Plains, New Jersey, 07950, United States

Location

Twelve Corners Pediatrics

Rochester, New York, 14618, United States

Location

Advanced Pediatrics

Vienna, Virginia, 22180, United States

Location

MeSH Terms

Interventions

Diagnosis

Study Design

Study Type
observational
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 23, 2011

First Posted

September 27, 2011

Study Start

June 1, 2011

Primary Completion

December 1, 2012

Study Completion

December 1, 2012

Last Updated

February 7, 2013

Record last verified: 2012-12

Locations